Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Zucara Therapeutics Inc., ("Zucara" or the "Company") a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent ...

Levemir (insulin detemir) has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin ... the cost of insulin products in the US marketplace – agreed ...

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine ... The move into supplying insulin products comes shortly after President Joe Biden called for a cap ...

“Supply chain issues and the dominance of a few pharmaceutical companies keep prices of some products high and ... the ...

Insulin pump therapy ... to consider the interactions of users with the technical features of their products is limited. The clinical studies required by regulators prior to marketing are small ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Sanofi, Breakthrough T1D UK, and Beano have partnered to create a bespoke comic strip to raise awareness of autoimmune Type 1 ...

Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.